Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.

Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H; GROUP investigators.

Eur Neuropsychopharmacol. 2012 Sep;22(9):625-31. doi: 10.1016/j.euroneuro.2012.01.006. Epub 2012 Mar 3.

2.

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.

Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Callegari-Jacques SM, Gesteira A, Barros F, Carracedo A, Hutz MH.

Pharmacogenet Genomics. 2008 Jul;18(7):599-609. doi: 10.1097/FPC.0b013e328301a763.

PMID:
18551040
3.

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, van Os J, Bruggeman R, Brouwers JR, van Harten PN.

J Psychopharmacol. 2009 Aug;23(6):652-9. doi: 10.1177/0269881108091594. Epub 2008 Jun 18.

PMID:
18562401
5.

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors.

Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, Matroos GE, van Os J, Hoek HW, van Harten PN.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):890-7. doi: 10.1002/ajmg.b.30746.

PMID:
18389501
6.

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, van Harten PN, Snieder H; Genetic Risk and Outcome in Psychosis (GROUP) investigators.

Psychopharmacology (Berl). 2012 Feb;219(3):727-36. doi: 10.1007/s00213-011-2394-1. Epub 2011 Jul 13.

PMID:
21750899
7.

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.

Gunes A, Scordo MG, Jaanson P, Dahl ML.

Psychopharmacology (Berl). 2007 Mar;190(4):479-84. Epub 2006 Nov 11.

PMID:
17102980
8.

Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.

Kang SG, Lee HJ, Choi JE, Park YM, Park JH, Han C, Kim YK, Kim SH, Lee MS, Joe SH, Jung IK, Kim L.

Neuropsychobiology. 2008;57(1-2):49-54. doi: 10.1159/000129667. Epub 2008 May 2.

PMID:
18451638
9.
10.

The COMT and DRD3 genes interacted in bipolar I but not bipolar II disorder.

Lee SY, Chen SL, Chen SH, Huang SY, Tzeng NS, Chang YH, Wang CL, Lee IH, Yeh TL, Yang YK, Lu RB.

World J Biol Psychiatry. 2011 Aug;12(5):385-91. doi: 10.3109/15622975.2010.505298. Epub 2010 Aug 10.

PMID:
20698735
11.

Association of polymorphisms in BDNF, MTHFR, and genes involved in the dopaminergic pathway with memory in a healthy Chinese population.

Yeh TK, Hu CY, Yeh TC, Lin PJ, Wu CH, Lee PL, Chang CY.

Brain Cogn. 2012 Nov;80(2):282-9. doi: 10.1016/j.bandc.2012.06.005. Epub 2012 Aug 31.

PMID:
22940753
12.

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N.

Pharmacogenomics J. 2003;3(6):356-61.

PMID:
14610521
13.

Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.

Liu YZ, Tang BS, Yan XX, Liu J, Ouyang DS, Nie LN, Fan L, Li Z, Ji W, Hu DL, Wang D, Zhou HH.

Eur J Clin Pharmacol. 2009 Jul;65(7):679-83. doi: 10.1007/s00228-009-0658-z. Epub 2009 Apr 25.

PMID:
19396436
14.

Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.

Sáiz PA, García-Portilla MP, Arango C, Morales B, Arias B, Corcoran P, Fernández JM, Alvarez V, Coto E, Bascarán MT, Bousoño M, Fañanas L, Bobes J.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):26-31. doi: 10.1016/j.pnpbp.2009.09.008. Epub 2009 Sep 17.

PMID:
19766158
16.
17.

Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.

Kao AC, Rojnic Kuzman M, Tiwari AK, Zivkovic MV, Chowdhury NI, Medved V, Kekin I, Zai CC, Lieberman JA, Meltzer HY, Bozina T, Bozina N, Kennedy JL, Sertic J, Müller DJ.

J Psychiatr Res. 2014 Jul;54:36-42. doi: 10.1016/j.jpsychires.2014.03.012. Epub 2014 Mar 21.

PMID:
24725652
18.

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.

Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH.

J Clin Psychopharmacol. 2005 Feb;25(1):6-11.

PMID:
15643094
19.

DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.

Bombin I, Arango C, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, Gonzalez-Gomez C, Moreno D, Parellada M, Baeza I, Graell M, Otero S, Saiz PA, Patiño-Garcia A.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):873-9. doi: 10.1002/ajmg.b.30710.

PMID:
18351593
20.

Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients.

Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL.

Hum Psychopharmacol. 2010 Apr;25(3):253-9. doi: 10.1002/hup.1111.

PMID:
20373477

Supplemental Content

Support Center